Gan & Lee Pharmaceuticals has received marketing authorization from the European Commission for its insulin lispro injection, Bysumlog®. This rapid-acting insulin analog is approved for treating diabetes in adults and children across the EU, Iceland, Liechtenstein, and Norway. The company has invested approximately 414 million yuan in its research and development. AI
Summary written by gemini-2.5-flash-lite from 1 source. How we write summaries →
RANK_REASON Product approval by a major regulatory body for a pharmaceutical company. [lever_c_demoted from significant: ic=1 ai=0.0]